

Adult CIRB - Early Phase Emphasis Meeting Agenda

July 7, 2026

I New Study - Initial Review

10740, A Phase 2 Trial of IMC-F106C, a PRAME Targeted ImmTAC, in Rare Cancers (Version Date 06/01/26)

II Amendment

10605, A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Cancer (Version Date 06/05/26)

III Continuing Review

10299, A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients (Version Date 05/19/26)

IV Continuing Review

10358, Phase 1/1B study of DS-8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial) (Version Date 04/15/25)

V Continuing Review

EAY191-A3, A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers (Version Date 09/04/24)

VI Amendment

10675, A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) (Version Date 05/28/26)

VII Continuing Review

10440, A Phase 1/1a Study of Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis (Version Date 02/04/26)
